• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "June, 2022"
 Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma
 0
By Nascent Biotech
In Corporate News
Posted June 14, 2022

Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma

Nascent Biotech Inc (OTCMKTS: NBIO) is making a steady run northbound off its base at a nickel and saw some of its biggest gains while the overall markets saw steep declines. NBIO is a low float [...]

READ MORE
 Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
 0
By Nascent Biotech
In Science News
Posted June 7, 2022

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.